Compare ASGN & DMRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ASGN | DMRA |
|---|---|---|
| Founded | 1985 | 2011 |
| Country | United States | United States |
| Employees | N/A | 7 |
| Industry | Professional Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.5B |
| IPO Year | 1996 | 2020 |
| Metric | ASGN | DMRA |
|---|---|---|
| Price | $19.79 | $20.94 |
| Analyst Decision | Sell | Buy |
| Analyst Count | 7 | 2 |
| Target Price | $38.43 | ★ $43.00 |
| AVG Volume (30 Days) | ★ 9.7M | 308.6K |
| Earning Date | 04-22-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.13 | N/A |
| Revenue | ★ $3,980,400,000.00 | N/A |
| Revenue This Year | $3.26 | N/A |
| Revenue Next Year | $4.94 | N/A |
| P/E Ratio | $150.62 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $19.31 | $16.50 |
| 52 Week High | $60.06 | $28.76 |
| Indicator | ASGN | DMRA |
|---|---|---|
| Relative Strength Index (RSI) | 18.34 | 36.58 |
| Support Level | N/A | N/A |
| Resistance Level | $47.94 | $27.70 |
| Average True Range (ATR) | 1.84 | 1.91 |
| MACD | -0.85 | -0.31 |
| Stochastic Oscillator | 1.21 | 29.72 |
ASGN Inc is a provider of information technology (IT) services and professional solutions, including technology, creative, and digital, across the commercial and government sectors. It operates through two segments, Commercial and Federal Government. The Commercial Segment, which generates the majority of the revenue, provides consulting, creative digital marketing, and permanent placement services to Fortune 1000 clients and mid-market companies. The Federal Government Segment provides mission-critical solutions to the Department of Defense, intelligence agencies, and civilian agencies.
Damora Therapeutics Inc is a biotechnology company that aims to fundamentally redefine care for people with hematologic disorders. The group is advancing a new generation of biologics to treat mutant calreticulin-driven myeloproliferative neoplasms, including essential thrombocythemia and myelofibrosis, where there is cruicial medical need for disease-modifying treatments. Its goal is to rapidly bring forward optimized therapies with broad mutation coverage and exceptional convenience to dramatically improve patient outcomes. The group's pipeline products are DMR-001, DMR-002, DMR-003, and GB3226.